GDEUX
Price
$22.04
Change
-$0.01 (-0.05%)
Updated
Sep 20 closing price
VFIAX
Price
$527.71
Change
-$1.02 (-0.19%)
Updated
Sep 20 closing price
Ad is loading...

GDEUX vs VFIAX

Header iconGDEUX vs VFIAX Comparison
Open Charts GDEUX vs VFIAXBanner chart's image
Goldman Sachs U.S. Equity ESG R6
Price$22.04
Change-$0.01 (-0.05%)
VolumeN/A
CapitalizationN/A
Vanguard 500 Index Admiral
Price$527.71
Change-$1.02 (-0.19%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
GDEUX vs VFIAX Comparison Chart
Loading...
VS
GDEUX vs. VFIAX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GDEUX is a Buy and VFIAX is a Buy.

FUNDAMENTALS
Fundamentals
VFIAX has more cash in the bank: 1.24T vs. GDEUX (28.9M). VFIAX pays higher dividends than GDEUX: VFIAX (1.32) vs GDEUX (0.72). GDEUX was incepted earlier than VFIAX: GDEUX (9 years) vs VFIAX (24 years). GDEUX is a more actively managed with annual turnover of: 34.00 vs. VFIAX (2.00). VFIAX has a lower initial minimum investment than GDEUX: VFIAX (3000) vs GDEUX (5000000). VFIAX (31.72) and GDEUX (31.04) have marching annual gain over last year. VFIAX return over 5 years is better than : 90.47 vs. GDEUX (62.71).
GDEUXVFIAXGDEUX / VFIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years24 years-
Gain YTD18.42119.97192%
Front LoadN/AN/A-
Min. Initial Investment50000003000166,667%
Min. Initial Investment IRAN/AN/A-
Net Assets28.9M1.24T0%
Annual Yield % from dividends0.721.3254%
Returns for 1 year31.0431.7298%
Returns for 3 years22.0530.9971%
Returns for 5 years62.7190.4769%
Returns for 10 yearsN/A190.48-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BLBD54.491.17
+2.19%
Blue Bird Corp
MPLX44.200.07
+0.16%
Mplx LP
AIP7.45-0.08
-1.06%
Arteris
FFIN38.10-0.74
-1.91%
First Financial Bankshares
TPST1.35-0.06
-4.26%
Tempest Therapeutics